Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed maintenance dosing strategies in patients with impaired renal function
2016-002552-24Phase 4Active
- Sponsor
- Centre Georges-François Leclerc
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Centre Georges-François Leclerc. Primary endpoint: Median time to treatment discontinuation for renal function <= 45 mL/min. Started Jan 2017; status: active.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-002552-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002552-24.